Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Aitken

Showing results (291-300 of 298) with videos related to

Pageof 30
Sort By:
You have reached the last page of results.This site can display upto 298 results.
Open Forum Infectious Diseases|October 30, 2019
Higher MICs (>2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> Treated With Ceftolozane/TazobactamOlga Rodríguez-Núñez, Leonor Periañez-Parraga, Antonio Oliver, et al.
Cell Host & Microbe|August 25, 2015
Regional Isolation Drives Bacterial Diversification within Cystic Fibrosis LungsPeter Jorth, Benjamin J Staudinger, Xia Wu, et al.
Emerging Infectious Diseases|February 26, 2014
High-level relatedness among Mycobacterium abscessus subsp. massiliense strains from widely separated outbreaksHervé Tettelin, Rebecca M Davidson, Sonia Agrawal, et al.
Open Forum Infectious Diseases|February 14, 2022
Contemporary Clinical and Molecular Epidemiology of Vancomycin-Resistant Enterococcal Bacteremia: A Prospective Multicenter Cohort Study (VENOUS I)German A Contreras, Jose M Munita, Shelby Simar, et al.
Cell Host & Microbe|August 6, 2025
Pseudomonas infections persisting after CFTR modulators are widespread throughout the lungs and drive lung inflammationSamantha L Durfey, Siddhartha G Kapnadak, Tahuanty Pena, et al.
The New England Journal of Medicine|November 19, 2010
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutationFrank J Accurso, Steven M Rowe, J P Clancy, et al.
Thorax|August 10, 2011
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutationJ P Clancy, Steven M Rowe, Frank J Accurso, et al.
The Lancet. Infectious Diseases|December 19, 2024
Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational studyRyan K Shields, Lilian M Abbo, Renee Ackley, et al.
Pageof 30

Showing results (291-300 of 298) with videos related to

Sort By:
Pageof 30
You have reached the last page of results.This site can display upto 298 results.
Open Forum Infectious Diseases|October 30, 2019
Higher MICs (>2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> Treated With Ceftolozane/TazobactamOlga Rodríguez-Núñez, Leonor Periañez-Parraga, Antonio Oliver, et al.
Cell Host & Microbe|August 25, 2015
Regional Isolation Drives Bacterial Diversification within Cystic Fibrosis LungsPeter Jorth, Benjamin J Staudinger, Xia Wu, et al.
Emerging Infectious Diseases|February 26, 2014
High-level relatedness among Mycobacterium abscessus subsp. massiliense strains from widely separated outbreaksHervé Tettelin, Rebecca M Davidson, Sonia Agrawal, et al.
Open Forum Infectious Diseases|February 14, 2022
Contemporary Clinical and Molecular Epidemiology of Vancomycin-Resistant Enterococcal Bacteremia: A Prospective Multicenter Cohort Study (VENOUS I)German A Contreras, Jose M Munita, Shelby Simar, et al.
Cell Host & Microbe|August 6, 2025
Pseudomonas infections persisting after CFTR modulators are widespread throughout the lungs and drive lung inflammationSamantha L Durfey, Siddhartha G Kapnadak, Tahuanty Pena, et al.
The New England Journal of Medicine|November 19, 2010
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutationFrank J Accurso, Steven M Rowe, J P Clancy, et al.
Thorax|August 10, 2011
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutationJ P Clancy, Steven M Rowe, Frank J Accurso, et al.
The Lancet. Infectious Diseases|December 19, 2024
Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational studyRyan K Shields, Lilian M Abbo, Renee Ackley, et al.
Pageof 30